Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy

International Journal of Hematology

Volumn 88, Issue 5, 2009, Pages 471-475

  Abe, Akihiro ^a   Minami, Yosuke ^a,b   Hayakawa, Fumihiko ^a   Kitamura, Kunio ^c   Nomura, Yuka ^a   Murata, Makoto ^a   Katsumi, Akira ^a   Kiyoi, Hitoshi ^d   Jamieson, Catriona H M ^b   Wang, Jean Y J ^b   Naoe, Tomoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Ichinomiya Municipal Hospital   (Japan)

^d NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CML; Imatinib; Leukemic stem cells; MRD

Indexed keywords

BCR ABL PROTEIN; IMATINIB; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; MESSENGER RNA; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; RNA;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CELL ISOLATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE IDENTIFICATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MINIMAL RESIDUAL DISEASE; MYELOID PROGENITOR CELL; REAL TIME POLYMERASE CHAIN REACTION; CANCER STEM CELL; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; REMISSION; TIME;

ADULT; FEMALE; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; NEOPLASTIC STEM CELLS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REMISSION INDUCTION; RNA, MESSENGER; RNA, NEOPLASM; TIME FACTORS;

EID: 64249111266     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0221-1     Document Type: Article

References (28)

1. C Sawyers 2004 Targeted cancer therapy Nature 432 294 7
2. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2408 17
3. HM Kantarjian J Cortes 2006 New strategies in chronic myeloid leukemia Int J Hematol 83 289 93
4. MW Deininger 2007 Optimizing therapy of chronic myeloid leukemia Exp Hematol 35 144 54
5. M Savona M Talpaz 2008 Getting to the stem of chronic myeloid leukaemia Nat Rev Cancer 8 341 50
6. J Cortes S O'Brien H Kantarjian 2004 Discontinuation of imatinib therapy after achieving a molecular response Blood 104 2204 5
7. F Michor TP Hughes Y Iwasa S Branford NP Shah CL Sawyers 2005 Dynamics of chronic myeloid leukaemia Nature 435 1267 70
8. S Merante E Orlandi P Bernasconi S Calatroni M Boni M Lazzarino 2005 Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation Haematologica 90 979 81
9. SM Graham HG Jorgensen E Allan C Pearson MJ Alcorn L Richmond 2002 Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood 99 319 25
10. X Jiang C Smith A Eaves C Eaves 2007 The challenges of targeting chronic myeloid leukemia stem cells Clin Lymphoma Myeloma 7 71 80
11. F Pellicano TL Holyoake 2007 Stem cells in chronic myeloid leukaemia Cancer Biomark 3 183 91
12. CH Jamieson LE Ailles SJ Dylla M Muijtjens C Jones JL Zehnder 2004 Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML N Engl J Med 351 657 67
13. I Roeder M Horn I Glauche A Hochhaus MC Mueller M Loeffler 2006 Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications Nat Med 12 1181 4
14. M Baccarani G Saglio J Goldman A Hochhaus B Simonsson F Appelbaum 2006 Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood 108 1809 20
15. SE Langabeer RE Gale RC Harvey RW Cook S Mackinnon DC Linch 2002 Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia Leukemia 16 393 9
16. T Hughes M Deininger A Hochhaus S Branford J Radich J Kaeda 2006 Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 28 37
17. JM Goldman 2007 How I treat chronic myeloid leukemia in the imatinib era Blood 110 2828 37
18. CH Jamieson J Gotlib JA Durocher MP Chao MR Mariappan M Lay 2006 The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation Proc Natl Acad Sci USA 103 6224 9
19. MG Manz T Miyamoto K Akashi IL Weissman 2002 Prospective isolation of human clonogenic common myeloid progenitors Proc Natl Acad Sci USA 99 11872 7
20. I Ishikawa C Kato H Harigae T Sugawara Y Tomiya M Yamada 2006 Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia Tohoku J Exp Med 210 355 63
21. S Branford TP Hughes Z Rudzki 1999 Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics Br J Haematol 107 587 99
22. E Diaz-Blanco I Bruns F Neumann JC Fischer T Graef M Rosskopf 2007 Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase Leukemia 21 494 504
23. AC Eaves CJ Eaves 1979 Abnormalities in the erythroid progenitor compartments in patients with chronic myelogenous leukemia (CML) Exp Hematol 7 Suppl 5 65 75
24. AC Eaves MJ Barnett L Ponchio JD Cashman AL Petzer CJ Eaves 1998 Differences between normal and CML stem cells potential targets for clinical exploitation Stem Cells 16 Suppl 1 77 83
25. AG Leary M Ogawa 1984 Identification of pure and mixed basophil colonies in culture of human peripheral blood and marrow cells Blood 64 78 83
26. JA Denburg S Telizyn H Messner B Lim N Jamal SJ Ackerman 1985 Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor Blood 66 312 8
27. R Bhatia M Holtz N Niu R Gray DS Snyder CL Sawyers 2003 Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment Blood 101 4701 7
28. R Majeti CY Park IL Weissman 2007 Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood Cell Stem Cell 1 635 45